bioMerieux : Early 2021 solid, visibility low beyond that – target price adjusted to € 115
>Visibility still uncertain in 2021 and a cautious tone - We took away the following points from yesterday’s conference call:1) On 2020: the FilmArray® installed base (17,300 systems, including 1,400 in Q4) has the same mix (one-third new customers), with 23% outside the US (vs 19% in 2019).In 2020, the COVID contribution before tax is estimated by BIM at c.€ 174m (no indication for 2021), reflecting the high profitability (> 35%e) of PCR tests (COVID contri...Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.